GE HealthCare’s first quarter results came in above Wall Street expectations, as the company delivered broad-based revenue growth across all business segments. Management credited strong U.S. demand for imaging equipment—particularly in cardiology and oncology—as well as robust order activity and backlog expansion, for the positive momentum. CEO Peter Arduini highlighted, “Record double-digit orders growth as a standalone company was driven by strength in the U.S. market, where we see customers prioritizing investments in imaging products.” The company also noted early market share gains and strong customer engagement as key contributors to the quarter’s performance.
Is now the time to buy GEHC? Find out in our full research report (it’s free).
GE HealthCare (GEHC) Q1 CY2025 Highlights:
- Revenue: $4.78 billion vs analyst estimates of $4.66 billion (2.8% year-on-year growth, 2.5% beat)
- Adjusted EPS: $1.01 vs analyst estimates of $0.91 (10.6% beat)
- Adjusted EBITDA: $826.9 million vs analyst estimates of $794.4 million (17.3% margin, 4.1% beat)
- Management lowered its full-year Adjusted EPS guidance to $4 at the midpoint, a 14.5% decrease
- Operating Margin: 13.2%, up from 11.6% in the same quarter last year
- Organic Revenue rose 4.1% year on year (-0.5% in the same quarter last year)
- Market Capitalization: $32.96 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions GE HealthCare’s Q1 Earnings Call
- Larry Biegelsen (Wells Fargo) asked about the timing and magnitude of tariff impacts and the pace of mitigation. CFO Jay Saccaro explained that most mitigation will be realized in the second half of the year and further improvements are targeted for 2026.
- Jason Bednar (Piper Sandler) inquired whether tariff mitigation actions were accelerated from long-range plans. CEO Peter Arduini clarified that while some actions were advanced, the broader margin and growth outlook remains unchanged.
- Vijay Kumar (Evercore ISI) questioned the proportion of tariff headwinds tied to U.S.-China trade and the potential upside if tariffs are eased. Saccaro detailed that bilateral tariffs account for the majority of the impact and that a rollback could deliver substantial upside to earnings.
- Robbie Marcus (JPMorgan) requested updates on Flyrcado’s launch and potential anti-dumping risks in China. Arduini confirmed Flyrcado is on track and stated that recent anti-dumping investigations are not expected to materially impact the business.
- Joanne Wuensch (Citi) probed the durability of hospital capital spending and the timeline for photon counting CT approval. Saccaro reported continued strength in U.S. and European demand, while Arduini reiterated that photon counting CT remains on schedule for regulatory submission.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will closely monitor (1) the pace and effectiveness of GE HealthCare’s tariff mitigation strategies, (2) progress on new product rollouts, including Flyrcado and photon counting CT, and (3) sustainability of order growth and backlog conversion, particularly in key markets like China and the U.S. Updates on supply chain adjustments and the impact of shifting trade policy will also be important indicators of execution.
GE HealthCare currently trades at $71.99, up from $68.09 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
